Anti-CD38 chimeric antigen receptor T cell therapy(Yake Biotechnology)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameAnti-CD38 chimeric antigen receptor T cell therapy(Yake Biotechnology)
Drug Alias NameCAR-T CD-38
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD38
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsMultiple MyelomaLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai YaKe Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai YaKe Biotechnology Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A